Anatomic Closure of the Premature Patent Ductus Arteriosus: The Role of CD14⁺/CD163⁺ Mononuclear Cells and Vascular Endothelial Growth Factor (VEGF) in Neointimal Mound Formation

Abstract

Permanent closure of the newborn ductus arteriosus requires the development of neointimal mounds to completely occlude its lumen. Vascular endothelial growth factor is required for neointimal mound formation. The size of the neointimal mounds (composed of proliferating endothelial and migrating smooth muscle cells) is directly related to the number of VLA4⁺ mononuclear cells that adhere to the ductus lumen after birth. We hypothesized that VEGF plays a crucial role in attracting CD14⁺/CD163⁺ mononuclear cells (expressing VLA4⁺) to the ductus lumen and that CD14⁺/CD163⁺ cell adhesion to the ductus lumen is important for neointimal growth. We used neutralizing antibodies against VEGF and VLA-4⁺ to determine their respective roles in remodeling the ductus of premature newborn baboons. Anti-VEGF treatment blocked CD14⁺/CD163⁺ cell adhesion to the ductus lumen and prevented neointimal growth. Anti-VLA-4 treatment blocked CD14⁺/CD163⁺ cell adhesion to the ductus lumen, decreased the expression of PDGF-B (which promotes smooth muscle migration), and blocked smooth muscle influx into the neointimal subendothelial space (despite the presence of increased VEGF in the ductus wall). We conclude that VEGF is necessary for CD14⁺/CD163⁺ cell adhesion to the ductus lumen and CD14⁺/CD163⁺ cell adhesion is essential for VEGF-induced expansion of the neointimal subendothelial zone.

Introduction

Closure of the full-term ductus arteriosus after birth occurs in two phases. First, smooth muscle constriction narrows the ductus’ lumen. Then, anatomic remodeling permanently occludes the lumen. In contrast with the full term ductus, the preterm ductus frequently fails to narrow its lumen or undergo anatomic remodeling. Remodeling of the preterm ductus will occur if it can be made to constrict tightly and obstruct luminal blood flow (1).

Several of the steps involved with ductus remodeling have been elucidated. The initial constriction creates a zone of ischemic hypoxia within the ductus’ muscle media that appears to be the required stimulus for the following anatomic changes: 1) formation of neointimal mounds (composed of proliferating luminal endothelial cells and migrating medial smooth muscle cells expanding the intima’s subendothelial space), 2) vasa vasorum proliferation within the muscle media, and 3) smooth muscle cell death (2). While the cell death and penetration of vasa vasorum into the ductus wall appear to be due to profound ATP depletion (3, 4) and vascular endothelial growth factor induction (5), respectively, the mechanism(s) responsible for the neointimal changes are still unknown.

In mice, platelets and platelet thrombi appear to be essential for permanent closure of the ductus lumen (6). In contrast, in human and non-human primates, recent studies suggest that platelets are not required for permanent ductus closure (7).

Inflammatory processes play a crucial role in the pathogenesis of several vascular disorders (8, 9). During atherogenesis, direct interactions between circulating monocytes and luminal endothelial cells increase the synthesis of factors like platelet derived growth factor (PDGF) and matrix metalloproteinase (MMP)-9, that facilitate the migration of smooth muscle cells into the expanding neointima (10, 11). We previously hypothesized that the attachment of circulating mononuclear cells to the ductus’ luminal endothelium may also be essential for ductus neointima formation (12). This hypothesis is supported by several observations: following ductus constriction, endothelial cells lining the lumen, increase their expression of vascular cell adhesion molecule-1 (VCAM-1), an important ligand for the mononuclear cell adhesion receptor, VLA-4 (also known as integrin α4β1 or CD49d) (12, 13); paralleling the increase in VCAM-1, VLA-4⁺ mononuclear cells increase their adherence to the ductus lumen (12); and, finally, the degree of VLA-4⁺ mononuclear cell adherence to the ductus lumen is associated with the extent of neointimal remodeling of the ductus (12).

The factors responsible for attracting circulating mononuclear cells to the ductus wall are still unknown. The hypoxia-inducible growth factor, VEGF appears to play an important role in ductus neointimal mound formation and vasa vasorum ingrowth (1, 5, 12). VEGF promotes the proliferation and migration of endothelial cells (14, 15). VEGF is also a direct chemoattractant for monocytes (16, 17)).

In the experiments described below, we used neutralizing antibodies against VEGF and VLA-4⁺ to determine their roles in mononuclear cell adhesion and ductus neointima formation in preterm baboons.

Methods

VLA-4 inhibition – in vivo

Animal experiments were approved (by the Institutional Animal Care and Use Committee) and performed at the Southwest National Primate Research Center in San Antonio, TX. Complete descriptions of the animal care and surgical procedures have been published elsewhere (5, 12). Briefly, timed pregnant baboon (Papio papio) dams were delivered by C-section at 125 + 1 days gestation (full term = 185 days); their fetuses were either (a) euthanized before breathing (Fetal Controls) or (b) mechanically ventilated for 6 days (Newborn groups) at which point the animals were euthanized. Preterm newborn baboons usually fail to constrict and obstruct their ductus luminal blood flow unless they are treated with inhibitors of both prostaglandin and nitric oxide production (1). Therefore, all preterm newborn baboons were treated with a combination of indomethacin (Indocin ®, 0.1 mg/kg/dose, given intravenously at 24, 48, 72, 84, 96, 108, 120 and 132 h after delivery) and N-nitro-L-arginine (a nitric oxide synthase inhibitor: 6 mg/kg/h as a continuous infusion, starting at 50 h after delivery and continuing until necropsy). Preterm newborn baboons were randomly assigned to one of three treatment groups: 1) Controls (no antibody treatment), 2) anti-VLA-4 treated newborns, and 3) anti-VEGF treated newborns. Because of the expense and need to restrict the use of this precious animal model, we were limited in the number of animals we could study. As a result, we were not able to have a Control group that received an isotype control antibody. The anti-VLA-4 newborns (group 2) received two intravenous doses (5 mg/kg) of HP1/2 (a humanized anti-VLA-4 monoclonal antibody (MAb) (Biogen Idec, Cambridge, MA) (18)) at 24 and 72 hr after delivery. Similar doses of HP1/2 have been shown to reduce mononuclear cell adhesion to arterial walls in mice (19), rabbits (20), pigs (21), and baboons (18). The anti-VEGF newborns (group 3) received a single intravenous dose (10 mg/kg) of a neutralizing monoclonal antibody made against VEGF (MAb A.4.6.1, Genentech, S. San Francisco, CA) (22, 23)) 24 hr after delivery (5). The animals in the anti-VEGF group (group 3) have been previously reported (5); however, the findings presented below were not included in the original report.

A complete echocardiographic examination including assessment of ductal patency was performed daily (1). At necropsy, the ductus was dissected in 4°C phosphate buffered saline solution and (a) embedded and frozen in Tissuetek (American Master Tech, Merced, CA) for immunohistochemistry (newborn baboon groups 1, 2, and 3), and/or (b) frozen in liquid nitrogen for RNA analysis (newborn baboon groups 1 and 2). Tissue was not available for RNA analysis from the group 3 animals.

Flow cytometry

To identify the cell populations most likely to be affected by the anti-VLA-4 antibody, HP1/2, we used multicolor direct immunofluorescence, as previously described (24, 25). The antibodies used were anti-human CD3 (clone SP34-2, BD Biosciences), CD8 (clone SK1, BD Biosciences), CD14 (clone 322A-1, Beckman-Coulter), CD31 (clone WM59, Biolegend), CD45 (clone DO58–1283, Biolegend), and CD49d (clone AF10, Biolegend).

Quantitative PCR (polymerase chain reaction)

Total RNA was isolated from each individual ductus (26). Gene expression was quantified using TaqMan Universal PCR master mix, Taqman probes, and ABI PRISM 7500 Sequence detection system as previously described (3, 26). The degree of expression of the gene of interest was determined using the relative gene expression method. Malate dehydrogenase (MDH) was used as an internal control to normalize the data (12, 27). ΔCT represents the difference in cycle threshold between the expression of the housekeeping gene, MDH, and the gene of interest. Each unit of ΔCT represents a 2-fold change in a gene’s mRNA. The more negative the ΔCT, the fewer the number of starting copies of a gene (mRNA).

We have previously shown that the expression of HIF1α mRNA in the ductus arteriosus correlates with the degree of smooth muscle hypoxia (3). In our real-time PCR experiments, we used HIF1α as a surrogate marker for hypoxia.

Immunohistochemistry

Immunohistochemistry protocols were similar to those reported previously (1, 12, 28). Endothelial cells were detected with anti-eNOS ({Clone 3} BD Biosciences, San Jose, CA) and anti-VE cadherin ({F-8} Santa Cruz Biotechnology, Santa Cruz, CA). Both antibodies showed identical findings. Monocytes/macrophages were detected with anti-CD163 ({GHI/61} Santa Cruz Biotechnology) or anti-CD14 ({TUKU} Dako, Carpenteria, CA). Both antibodies showed identical findings. Antibodies against the following antigens were used to identify T-lymphocytes (CD3 {rabbit polyclonal} Dako), T cells/NK cells (CD8 {UCH-T4} Santa Cruz Biotechnology), dendritic cells (CD83 {HB15a} Santa Cruz Biotechnology), and granulocytes (neutrophil elastase {NP57} Dako). Antibodies against GP1bα ({AN51} Dako) were used to identify platelets. Antibodies against VCAM-1 ({1G11} Santa Cruz Biotechnology) were used to identify adhesion molecules expressed by activated endothelial cells. The number of positively stained cells lining the ductus lumen was expressed per 100 luminal-lining cells.

Histologic measurements in the newborn ductus were made at the level of minimal luminal area, which was determined from 6µm serial cross-sections. The neointimal zone was defined as the region between the lumen and the internal elastic lamina (identified by phase contrast microscopy). The endothelial zone of the neointima was the luminal cell layer(s) that stained positive for eNOS (endothelial nitric oxide synthase) and VE-cadherin (vascular endothelial cell cadherin). The subendothelial zone was defined as the region between the luminal endothelial cells and the internal elastic lamina. Neointimal dimensions were determined by averaging measurements made from eight predetermined regions of the section, using an overlay template and NIH ImageJ software.

Mononuclear cells and vasa vasorum invade the ductus muscle media from the surrounding adventitia (see below). To determine the extent of muscle media invasion by mononuclear cells and vasa vasorum, we used an overlay template, containing a grid, and NIH ImageJ software to divide the muscle media into eight clock-hours sections. In each section of the wall, we measured the maximal distance that the cells migrated from the adventitia into the media (expressed as a percent of the distance from the adventitia to the internal elastic lamina in that section of the wall). The maximal distances from each of the eight sections of the ductus wall were averaged and reported as “% muscle media thickness” for that vessel.

Statistics

Results are presented as means ± standard deviations (SD) and percentages. Intergroup differences were evaluated with either a Chi-Square analysis, or unpaired t-test. When more than one comparison was made, Bonferroni’s correction was used.

Results

Combined treatment with indomethacin and N-nitro-L-arginine produced constriction of the ductus arteriosus and complete loss of Doppler-demonstrable luminal blood flow in all of the preterm newborn baboons. Neither the anti-VLA-4 MAb, nor the anti-VEGF MAb, affected the rate of ductus constriction measured by daily pulsed-Doppler exams (age of Doppler-demonstrable ductus closure: group 1 (Control newborns, n=18) = 79±31 hours; group 2 (anti-VLA-4, n=8) = 91±28 hours; group 3 (anti-VEGF, n=6) = 88±24 hours).

We used HIF1α mRNA expression as a surrogate marker for ductus hypoxia. There was a significant increase in HIF1α expression between fetus and newborns following postnatal closure (Table 1) (3), however, there was no difference in HIF1α expression between newborns in the Control group (group 1) and those treated with anti-VLA-4 MAb (group 2) (Table 1). Nor were there differences in the degree of hypoxia between the Control (group 1) and the anti-VEGF treated newborns (group 3) (previously reported in (5).

Table 1. Effects of ductus treatment on Real Time polymerase chain reaction (PCR) measurements of molecules involved with ductus arteriosus closure.

Fetal ductus obtained from 125 days gestation baboons (n=10 separate animals), were compared with ductus from Control premature newborns (n=10 separate animals) and from preterm newborns treated with HP1/2 (anti-VLA-4 MAb) (n=6 separate animals). ΔCT represents the difference in cycle threshold (CT) between the expression of the housekeeping gene Malate dehydrogenase (MDH) and the gene of interest. Each unit of ΔCT represents a 2-fold change in a gene’s mRNA. The more negative the ΔCT, the fewer the number of starting copies of a gene (mRNA).

	Fetus		Newborn Control		Newborn Anti-VLA-4
	ΔCT (MDH – gene)		ΔCT (MDH – gene)		ΔCT (MDH – gene)
	mean	SD	mean	SD	mean	SD
CD14	−5.01	0.37	−3.20 *	0.33	−4.28 *†	0.42
PTGS1/COX-1	−5.72	0.51	−4.31 *	0.64	−5.41 †	0.60
PTGS2COX-2	−6.96	0.88	−5.26 *	0.82	−5.43 *	0.85
NOS3/eNOS	−6.07	0.59	−4.35 *	1.13	−4.84 *	0.25
FLT1/FLT-1	−2.99	0.33	−2.28 *	0.44	−2.19 *	0.40
HIF1a/HIF1α	−3.72	0.23	−1.46 *	0.28	−1.69 *	0.39
IFNG/IFNα	−6.21	1.10	−2.37 *	0.53	−3.29 *†	0.81
IL6/IL-6	−5.49	1.07	−2.71 *	0.88	−2.97 *	0.84
IL8/IL-8	−6.03	0.92	−2.56 *	0.51	−2.93 *	0.91
CSF1/MCSF	−3.60	0.81	−1.27 *	0.74	−1.43 *	0.94
MMP9/MMP-9	−3.47	0.69	−1.09 *	0.50	−2.05 *†	0.53
PDGF-B	−4.69	0.60	−2.25 *	0.35	−2.96 *†	0.50
PTGIS	1.45	0.79	0.39 *	0.82	0.08 *	0.97
TGFB1/TGFβ1	−5.74	0.43	−3.87 *	0.56	−4.93 *†	0.64
TNFA/TNFα	−9.98	0.49	−8.72 *	0.71	−9.22	1.18
VCAM-1	−4.93	0.64	−2.48 *	0.29	−2.42 *	0.34
CDH5/VE-cadherin	−2.35	0.40	−1.12 *	0.12	−1.57 *	0.39
VEGFA	−3.24	0.28	−0.41 *	0.78	−0.84 *	0.88

FLT, fms-related tyrosine kinase; IL, interleukin; MCSF, colony stimulating factor 1 (macrophage); PTGIS, prostacyclin synthase

^*p < 0.05 vs fetal ductus;

^†p < 0.05 vs newborn control ductus.

Distribution of VLA-4 (CD49d) on baboon leukocytes

To identify the cell populations most likely to be affected by the anti-VLA-4 antibody, HP1/2, we used flow cytometry to determine the distribution of expression of VLA-4 on umbilical cord blood leukocytes obtained from 4 fetal baboons. VLA-4 was expressed on the surface of 64±17% (mean ±SD) of baboon monocytes (defined as CD45+ CD14+ or CD45+ CD163+ cells), and 0±0% of baboon granulocytes (large cells that were CD45+ and CD14−CD163−). This distribution is similar to what we observed in human cord blood monocytes (80±18% expressed VLA-4) and granulocytes (0±0%). On the other hand, the percentage of baboon T-cells that expressed VLA-4 was significantly less than the percentage of human T-cells that expressed VLA-4: CD4+ T-cells (defined as CD45+ CD3+ CD14− CD8−) cells: baboon = 8±2%, human = 84±7% expressed VLA-4; CD8+ T-cells (defined as CD45+ CD3+ CD14− CD8+) cells: baboon =18±5%, human = 97±3% expressed VLA-4. Therefore, we anticipated that, in the baboon, the anti-VLA-4 MAb, HP1/2, would primarily affect CD14+/CD163+ cells (monocytes) from adhering to the luminal endothelium.

Anti-VLA-4 experiments

Following delivery of the Control newborns, there was an increase in expression of VCAM-1 (the ligand for the monocyte VLA-4 receptor (13)) on ductus luminal endothelial cells (Figure 1; Tables 1, 2), as well as an increase in the number of CD14⁺ and CD163⁺ cells (monocytes) (Figure 2; Table 2), CD3⁺ cells (data not shown), and CD8⁺ T-cells (Figure 2; Table 2) adhering to the ductus luminal endothelium. We found no evidence of platelets (GP1bα⁺ cells), neutrophils (neutrophil elastase⁺ cells), or dendritic (CD83⁺) cells adhering to the fetal or neonatal ductus lumen (data not shown).

Figure 1.

VCAM-1 (A–D) and eNOS (E–H) expression in cells lining the ductus lumen. Endothelial cells were detected by eNOS expression. Ductus come from fetuses (A,E) and neonates exposed to Control conditions (B,F), anti-VLA-4 (C,G) or anti-VEGF (D,H) antibodies. Small arrows (A–D) indicate brown immunostained cells. Nuclei counterstained with hematoxylin (blue). Dashed black line = internal elastic lamina (identified by phase-contrast microscopy). Horizontal bar = 50 µm.

Table 2. Effect of ductus treatment on VCAM-1 expression and mononuclear cell adhesion to the ductus lumen (immunohistochemistry).

The number of endothelial cells lining the ductus lumen that are positive for VCAM-1, and the number of VLA-4, CD163, CD14, or CD8 positive mononuclear cells that adhere to the ductus luminal wall, are expressed per 100 lumen-lining cells.

	Positive expressing cells/100 luminal cells
	Fetus	Newborn Control	Newborn Anti-VLA-4	Newborn Anti-VEGF
	(N=7)	(N=14)	(N=7)	(N=6)
VCAM-1	0±0	4±4*	3±4*	4±4*
VLA-4	0±0	4±2*	NA	0±0†
CD163	0±0	7±4*	2±2†	0±1†
CD14	0±0	6±4*	2±2†	1±1†
CD8	0±0	7±5*	4±3*	4±3*

^*p < 0.05 vs fetal ductus;

^†p < 0.05 vs newborn control ductus.

N, number of ductus examined. NA, tissue could not be examined because the monocyte VLA-4 receptors were already saturated with the HP1/2 anti-VLA-4 MAb.

Figure 2.

Adherence of CD14⁺ (A–D) and CD8⁺ (E–H) cells to the ductus luminal surface. Small arrows indicate brown immunostained cells. See legend Figure 1.

Treatment with the anti-VLA-4 MAb did not alter the expression of VCAM-1 on the luminal endothelium (Figure 1; Tables 1, 2), but inhibited CD14⁺ cells and CD163⁺ cells (monocytes) (Figure 2; Tables 1, 2) from adhering to the ductus lumen. CD8⁺ T-cells did not appear to be affected by the anti-VLA-4 MAb treatment (Figure 2; Table 2).

Many of the genes that are essential for vascular remodeling are expressed by the ductus after postnatal constriction (Table 1) (12). Treatment with the anti-VLA-4 MAb decreased the expression of cyclooxygenase-1, IFNγ, MMP-9, PDGF-B chain, and TGFβ1 in the ductus wall (Table 1), which suggests that VLA4⁺/CD14⁺/CD163⁺ cell adhesion to the ductus lumen may be responsible, in part, for their expression.

The ductus of the Control newborn animals (group 1) developed the same anatomic changes that have previously been observed when postnatal constriction produces profound ductus wall hypoxia (1, 2, 5, 12). The Control newborn ductus developed a significantly thicker neointima than the fetal ductus (Figure 1, Table 3). The neointima was composed of an endothelial zone (filled with multiple layers of endothelial cells) and an expanding subendothelial zone (Figure 1, Table 3) (filled with non-endothelial cells that expressed α-smooth muscle actin (data not shown)).

Table 3. Effect of anti-VLA-4 and anti-VEGF treatment on ductus neointima and vasa vasorum remodeling (see Methods for definitions).

A) Luminal endothelial thickness: number of ductus in each group that have either a single or multiple (2, 3 or more) layers of endothelial cells that completely surround the ductus lumen (Chi-Square analysis). B) Neointimal (endothelial, subendothelial and total) thickness: Total thickness is the distance between the lumen and the internal elastic lamina. C) Subendothelial zone thickness > 20 µm: this represents the percentage of the luminal circumference that is surrounded by a thickened (> 20 µm) subendothelial zone. D) Vasa vasorum ingrowth: the distance that vasa vasorum migrate from the adventitia into the muscle media is expressed as the percentage of muscle media thickness.

	Fetus	Newborn Control	Newborn Anti-VLA-4	Newborn Anti-VEGF
	(N=7)	(N=14)	(N=7)	(N=6)
A) Luminal endothelial thickness		*	*	* †
1 layer – n (%)	7 (100)	0 (0)	0 (0)	1 (17)
2 layers – n (%)	0 (0)	2 (14)	2 (30)	4 (67)
≥ 3 layers – n (%)	0 (0)	12 (86)	5 (70)	1 (17)
B) Neointimal thickness
Endothelial zone - µm	8±1	62±38 *	53±25 *	24±10 * †
Subendothelial zone - µm	20±14	66±29 *	27±12 †	19±10 †
Total thickness - µm	29±14	128±47 *	81±30 †	44±10 * †
C) Subendothelial zone > 20 µm
% circumference of lumen	18±7	60±23 *	20±10 †	15±7 †
D) Vasa vasorum ingrowth
% muscle media thickness	8±4	14±6 *	14±6 *	5±3 †

^*p < 0.05 vs fetal ductus;

^†p < 0.05 vs newborn control ductus.

N, number of ductus examined.

Treatment with the anti-VLA-4 MAb inhibited neointimal expansion (Figure 1, Table 3). The anti-VLA-4 MAb had no effect on the postnatal increase in the number of endothelial cell layers but blocked the influx of non-endothelial cells into the subendothelial zone (Figure 1, Table 3).

After birth, vasa vasorum invade the muscle media from the adventitia of the preterm ductus (1, 5, 12). Prior studies have shown that resident CD14⁺ and CD68⁺ mononuclear cells are present in the adventitia and outer muscle media of the fetal ductus (12). These mononuclear cells invade the muscle media after birth and the extent of their invasion correlates with the extent of vasa vasorum penetration into the muscle media (12). We found that treatment with the anti-VLA-4 MAb had no effect on either the postnatal invasion of CD14⁺, CD163⁺, or CD8⁺ cells (Figure 3, Table 4) or the penetration of vasa vasorum into the muscle media (Table 3).

Figure 3.

Invasion of CD14⁺ (A–D) and CD8⁺ (E–H) cells into the ductus muscle media. Long arrows indicate the furthest distance brown immunostained cells have migrated from the adventitia in this particular visual field. Horizontal bar = 50 µm.

Table 4.

Effect of ductus treatment on invasion of ductus muscle media by VLA-4⁺, CD163⁺, CD14⁺ and CD8⁺ cells (expressed as percentage of muscle media thickness containing positive-expressing cells (see Methods)).

	% muscle media thickness
	Fetus	Newborn Control	Newborn Anti-VLA-4	Newborn Anti-VEGF
	(N=7)	(N=14)	(N=7)	(N=6)
VLA-4	1±3	15±6*	NA	3±5†
CD163	2±3	18±6*	20±7*	3±6†
CD14	1±3	16±6*	18±6*	2±5†
CD8	8±5	23±11*	18±9*	19±11*

^*p < 0.05 vs fetal ductus;

^†p < 0.05 vs newborn control ductus.

N, number of ductus examined. NA, tissue could not be examined because the monocyte/macrophage VLA-4 receptors were already saturated with the HP1/2 anti-VLA-4 MAb.

Anti-VEGF experiments

Treatment with the neutralizing anti-VEGF MAb did not alter the expression of VCAM-1 on the luminal endothelium (Figure 1, Table 2), but inhibited CD14⁺ and CD163⁺ cells (Figure 2; Table 2) from adhering to the ductus lumen. CD8⁺ T-cells did not appear to be affected by the anti-VEGF MAb treatment (Figure 2; Table 2).

Treatment with the anti-VEGF MAb decreased the postnatal neointimal expansion by reducing the number of endothelial cell layers and by completely blocking the influx of non-endothelial cells into the subendothelial zone of the neointima (Figure 1, Table 3).

The anti-VEGF MAb also blocked VLA-4⁺, CD14⁺ and CD163⁺ mononuclear cells from migrating into the outer muscle media (Figure 3, Table 4) and inhibited vasa vasorum penetration into the muscle media (Table 3) (5). The anti-VEGF MAb did not appear to affect migration of CD8⁺ cells into the outer muscle media (Figure 3, Table 4).

Discussion

The mechanisms responsible for leukocyte attachment, during ductus arteriosus remodeling, differ significantly from those involved in other “injury-induced” models of vascular remodeling. In most vascular injury models, leukocyte recruitment depends on the induced expression on the endothelial cell surface of P-selectin, E-selectin, ICAM-1, and VCAM-1 (29–31). Leukocyte interactions with both P-selectin and ICAM-1 appear to be necessary for recruitment to occur when physiologic shear forces are present (30, 32). Interactions between VCAM-1 and VLA-4 (the integrin receptor for VCAM-1) are capable of mediating leukocyte rolling and adhesion, without the need for selectins or β2 integrin/ICAM-1 interactions, but only when very low flow conditions exist (33–35).

During ductus closure, the ductus luminal endothelial cells have a very limited pattern of adhesion molecule expression (E-selectin and VCAM-1 are the only ones expressed) (12). As a result, leukocytes fail to attach in the presence of physiologic shear forces (12). VLA-4⁺ leukocytes can adhere to the ductus wall, but only after tight constriction and loss of luminal flow have occurred (12).

We found that VLA-4 was most frequently expressed by baboon CD14⁺ and CD163⁺ cells (monocytes), less frequently by T-lymphocytes, and not at all by neutrophils. These findings help to explain why neutrophils, which normally contribute to most inflammatory conditions, are notably absent during ductus closure (see Results and (12)). They also explain why the anti-VLA-4 MAb primarily blocked CD14⁺ and CD163⁺ mononuclear cells from attaching to the ductus luminal endothelium (Figure 2, Tables 1, 2). The VLA-4 MAb also appeared to have little effect on the postnatal migration of CD14⁺, CD163⁺, or CD8⁺ cells from the adventitia into the muscle media (Figure 3, Table 4).

The present experiments demonstrate that after birth, there is increased synthesis of PDGFB chain, MMP-9, COX-1, TGFβ, and IFNγ (Table 1) as well as smooth muscle migration into the neointima of the tightly constricted ductus arteriosus (Figure 1, Table 3). The anti–VLA-4 MAb inhibited these events from occurring (Figure 1, Tables 1,3). VLA4⁺/CD14⁺/CD163⁺ monocytes are the likely candidates for promoting smooth muscle cell migration into the neointima. They have the capacity to secrete proteolytic enzymes (e.g., MMP-9 (Table 1)), which are capable of degrading the extracellular matrix surrounding smooth muscle cells (9), and chemotactic substances for smooth muscle cell migration (e.g., PDGF (Table 1) (36)). We hypothesize that during ductus closure, monocyte-stimulated PDGF-B production may be one of the mediators of smooth muscle cell migration, as it is in other experimental models of neointimal thickening (37).

It is possible that the anti–VLA-4 MAb could have effects on cells other than monocytes that would affect ductus arteriosus cells and gene expression; however, it is unlikely that the anti–VLA-4 MAb exerted a direct suppressive effect on smooth muscle cell migration because VLA-4 is not detected on ductus smooth muscle cells (12).

Although the expansion of the subendothelial zone of the neointima appears to depend on VLA4⁺/CD14⁺/CD163⁺ monocytes adhering to the ductus lumen, the proliferation and layering of endothelial cells within the neointima appear to be independent of VLA4⁺/CD14⁺/CD163⁺ cell attachment (Figure 1, Table 3). Other mechanisms (e.g., VEGF) must be responsible for regulating ductus endothelial proliferation. Although VEGF is essential for luminal endothelial cell layering (Figure 1, Table 3) (5), additional factors must contribute to the luminal endothelial cell proliferation since ductus treated with the anti-VEGF MAb still had a thicker luminal endothelial zone than fetal ductus (Table 3).

In addition to its effects on luminal endothelial cell proliferation, VEGF plays an essential role in smooth muscle cell expansion of the ductus neointima and vasa vasorum ingrowth (5). Our current studies demonstrate that VEGF is necessary for the adherence of VLA4⁺/CD14⁺/CD163⁺ cells (monocytes) to the ductus lumen (Figure 2, Table 2). The VLA-4 dependent, CD14⁺/CD163⁺ cell adhesion to the ductus lumen appears to be essential for the VEGF-induced subendothelial expansion of the neointima; when VLA4⁺/CD14⁺/CD163⁺ cells are prevented from adhering to the ductus lumen by the MAb against VEGF, smooth muscle cell expansion of the neointima fails to occur (Figure 1, Table 3) despite the presence of increased VEGF in the ductus wall (Table 1).

It is also intriguing to speculate that CD14⁺/CD163⁺ cell migration may play a significant role in the VEGF-induced vasa vasorum ingrowth, since vasa vasorum ingrowth was only observed in association with CD14⁺ and CD163⁺ cell (macrophage) invasion (Tables 3 and 4).

Our current findings are consistent with the hypothetical model depicted in Figure 4. If VEGF and VLA4⁺/CD14⁺/CD163⁺ monocyte recruitment are central to ductus remodeling, then the current studies help to explain why tight ductus constriction and loss of luminal flow are essential for remodeling and permanent closure after birth (1, 2). Decreased luminal flow has a direct effect on VEGF and VCAM-1 expression (38). Decreased flow also enables the VLA4⁺/CD14⁺/CD163⁺ monocytes to adhere to the ductus wall through VCAM-1/VLA-4 interactions. Once the VLA4⁺/CD14⁺/CD163⁺ monocytes adhere to the ductus wall, the subsequent neointimal expansion helps to permanently plug the residual lumen.

Figure 4.

Hypothetical model of critical events in ductus arteriosus anatomic remodeling.

Abbreviations

COX

cyclooxygenase

ΔCT

the difference in cycle threshold between the expression of the housekeeping gene MDH and the gene of interest

eNOS

endothelial nitric oxide synthase

HP1/2

monoclonal antibody against VLA-4

MDH

Malate dehydrogenase

MMP-9

matrix metalloproteinase-9

VCAM-1

vascular cell adhesion molecule-1

VE

vascular endothelial cell

VLA-4 or CD49d

α4β1 integrin mononuclear cell adhesion receptor